We are pleased to announce the first International Conference on Antioxidants: Sources, Methods, Health Benefits, and Industrial Applications.
The conference is organized by the MDPI open access journal Antioxidants (Impact Factor 7.675) and will be held as a three-day event in Barcelona, Spain, 10-12 May, 2023.
Antioxidants represent a huge area of investigation for researchers
from many disciplines, and their importance in a variety of fields from
health to food to innovative materials is increasingly appreciated.
Despite the enormous amount of research work related to this issue,
our knowledge needs to be improved on the mechanism of action, the
bioaccesibility and bioavailability of dietary antioxidants, oxidative
stress and antioxidant defence systems, antioxidant-based therapeutic
strategies, antioxidant functional food, and the design of biomaterials
with antioxidant properties for use in biomedical applications or
functional packaging. We have to continue pursuing the search for new
natural sources of antioxidants while shifting toward sustainable
methodologies for their extraction, and, finally, we need to standardize
and validate the methods for their analysis and for evaluating and
ranking the antioxidant power.
The main topics and sessions of the conference will cover:
The conference will host a number of internationally renowned
speakers and invites submissions for oral presentations and posters. We
wish the meeting may offer a unique opportunity for direct communication
between scholars, favoring personal contacts between younger and
experienced researchers on advanced research topics and technological
All presenters at the conference will be encouraged to submit a full
manuscript of their presentation for consideration for publication in a
Special Issue of Antioxidants .
We look forward to seeing you at this exciting meeting in Barcelona.
SPECIAL OFFER – 10% discount for ICQA members.
Abstract submission is now open until 20th January 2023:
The International CoQ10 Association and Antioxidants journal has agreed to publish a special issue titled The Ubiquitous and Multifaceted Coenzyme Q, which will cover the new discoveries and research perspectives on CoQ and its role in health and diseases, and its importance in cellular redox homeostasis. A particular focus will be on studies on its biosynthesis and regulation. We invite all participants of the 10th International Scientific Meeting (Hamburg, May 12-15, 2022) to contribute to this special issue with original articles and reviews based on their recent results or expertise presented in the meeting.
Abstracts of 5 young student researchers will be chosen for the Young Participants Award. The name of the young authors must appear first in the author list and the abstract should be specified as a candidate for the award. Winners will have free registration and 5 mins to present their abstracts at the end of the specific session.
The following hotels have reduced rates for ICQA delegates from 11.05.2022 to 15.05.2022. When booking please specify the promotion code.
Dorint Hotel Hamburg-Eppendorf
Martinistrasse 72, 20251 Hamburg
134€/night single room
164€/night double room
30.03.22 remaining unreserved
rooms go on sale to the public
To apply please send a CV including a statement of research interests and names of 2 references to: Catarina M Quinzii (email@example.com), by February 29, 2020. Selected applicants will be invited to an interview in person or via Skype. Candidates will be informed about the selection by March 2020 with a projected June 2020 start date. The selected candidate must submit the necessary documents to Columbia University. Foreign applicants are encouraged to apply early to ensure adequate time to obtain visas
Alberto Sanz, PhD
Principal Research Associate
Institute for Cell and Molecular Biosciences &
Newcastle University Institute for Ageing
Campus for Ageing and Vitality
Newcastle upon Tyne
United Kingdome-mail: firstname.lastname@example.org
Tel: +44191 208 1221
Seville/Madrid, 2nd November 2016. The European Medicines Agency (EMA) has designated Ubiquinol as an orphan drug for the treatment of primary coenzyme Q10 deficiency, a serious rare disease which produces muscular, nervous system and kidney disorders and can cause failures of other organs.